TCP-25 Gel
Epidermolysis Bullosa (EB) wounds / Complex skin wounds
Phase 2Active
Key Facts
Indication
Epidermolysis Bullosa (EB) wounds / Complex skin wounds
Phase
Phase 2
Status
Active
Company
About Xinnate
Xinnate is a clinical-stage biotech leveraging a platform of innate immune-derived peptides to treat complex skin diseases characterized by dysfunctional healing. Its lead asset, TCP-25 Gel, is a multifunctional therapeutic with a dual mechanism of action that dampens harmful inflammation and directly kills microbes, including antibiotic-resistant strains. The company has initiated a clinical study (STEP) in Epidermolysis Bullosa and is building a robust global IP portfolio. Xinnate represents a novel approach to wound healing by modulating the local immune environment rather than merely addressing symptoms.
View full company profile